STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit

Eli Lilly's retatrutide, a next-generation obesity drug, showed significant weight loss in a Phase 3 study of 2,000 participants with severe obesity and heart disease, but did not demonstrate a statistically significant reduction in cardiovascular risk. The trial was not designed to assess cardiovascular outcomes, and event rates were lower than expected.